The recent discovery of 'leptin', the product of the mouse obese gene that appears to be a satiety factor, has electrified the field of obesity research.
Events of the past twelve months have had an explosive impact on the field of obesity research. This wave of excitement was triggered by a momentous announcement from Zhang et al. [1] in December 1994. The authors reported that they had identified the gene responsible for obesity in one of the most intensively studied genetic rodent models of the disorder, the ob/ob mouse, homozygous for a mutant form of the obese (ob) gene. It turned out that the normal ob gene is expressed only in fat tissue; it encodes a protein, OB, of molecular weight -18 kDa, which contains an -2 kDa cleavable leader sequence, indicating that it is a secreted product. The ob gene product appears to be highly conserved among vertebrates, the mouse and human homologues being 84 % identical at the amino-acid level. The mutation in C57BL/6J strain ob/ob mice introduces a stop codon into the ob mRNA, causing failure to produce normal OB protein and, interestingly, a 20-fold overexpression of the useless mRNA in white fat. A second mutation is found in ob2J/ob2J mice; in this case, the mutation occurs in the 5' region of the ob gene and prevents the synthesis of any ob mRNA [1] .
Soon after this breakthrough, three laboratories reported simultaneously [2] [3] [4] that administration of recombinant OB protein to ob/ob mice corrected both their overeating (hyperphagia) and their obesity. The protein was accordingly named leptin by Friedman's group, from the Greek word leptos, meaning thin [3] . Leptin is readily detectable immunologically as a 16 kDa monomer in plasma from normal mice and lean, healthy humans [3] , but it cannot be detected in plasma and adipose tissue of ob/ob mice. Leptin is, however, overexpressed in these compartments in another strain of genetically obese mice -those homozygous for a mutant form of the diabetic (db) gene; leptin is ineffective at reducing the weight of db/db mice [3, 4] . In addition to curbing food intake and reducing body weight, leptin corrects the hyperglycemia, hyperinsulinemia, hypometabolism and hypoactivity of ob/ob mice [2, 3] ; leptin also reduces the appetite and weight of mice with diet-induced obesity [4] . Leptin causes significant loss of body weight and fat content even in lean mice [2] [3] [4] , and it is effective whether given parenterally or injected directly into the lateral ventricle of the brain [4] . This impressive body of evidence clearly implicates leptin as an important factor in the regulation of food intake and general body state ('habitus'). This notion also appears to fit nicely with the thinking of some far-sighted early physiologists, who grappled with the question of how satiety and body weight are controlled. Thus, it was suspected a half century ago that the central nervous system (CNS), in particular the hypothalamus, plays a pivotal role in the regulation of body weight. In 1953, Kennedy [5] went further, postulating that body weight is regulated through a lipostatic mechanism involving an interaction between the hypothalamus and some factor in equilibrium with stored fat. Subsequently, Hervey [6] surgically linked normal rats, allowing partial exchange of blood between them ('parabiosis'), and electrically lesioned the hypothalamus of one member of each pair. The lesioned animals became hyperphagic and obese, while their partners developed anorexia and died of starvation. Hervey reasoned that, with increasing adiposity, a humoral factor accumulates and serves to control food intake through a feedback interaction with the hypothalamus; such a factor would, by definition, be ineffective in the lesioned rats, but it would be passed via the circulation into the non-lesioned parabionts and would suppress their food intake [6] .
With the advent of genetically obese -ob/ob and db/db -mice, it became possible to test the effect of parabiosis between the fat and lean animals in various combinations. From a classic study of this type, Coleman [7] inferred that the ob/ob mouse must lack the circulating satiety factor, while the db/db strain fails to respond to it, thus accounting for the similarity of the two phenotypes when present on the same genetic background [7] . In light of the newer findings, it seems likely that this longsought satiety factor is in fact leptin. If so, the transition from concept to reality must be regarded as a giant leap for mousekind. Like all major scientific advances, however, it brings with it a host of pressing questions. Some are touched upon below.
Where does leptin work? Current speculation that its primary site of action is in the hypothalamus (Fig. 1) is now beginning to receive experimental support. Thus, Stephens et al. [8] have established that, in association with its weight-reducing activity, leptin treatment also normalizes the elevated levels of neuropeptide Y (NPY) mRNA in the hypothalamus of the ob/ob mouse. Of particular interest is the preliminary evidence the authors have provided for the presence of a leptin receptor in the (rat) hypothalamus (tentatively localized to the arcuate nucleus), and for the ability of leptin to suppress NPY release from this site. If these findings are confirmed and shown to have specificity for leptin at physiological concentrations, they could be of great importance, in the light of the fact that overproduction of NPY has been strongly implicated in the genesis of rodent obesity [9] . In any event, the task of establishing a leptin-hypothalamus linkage will be greatly facilitated when the gene responsible for the mouse db mutation has been characterized. It will then be necessary to determine whether the normal DB protein really is a hypothalamic receptor for leptin, and that the receptor function is defective in the obese db/db mouse, as presently assumed [1, 3, 4, 8] .
What does leptin control? Given leptin's perceived role as an appetite suppressant, its circulating level would be predicted to rise as adipose tissue mass expands (see below) and somehow to diminish the drive to eat (presumably acting via the hypothalamus). If this is true, and if leptin is the satiety factor referred to by earlier workers [5] [6] [7] , then it presumably functions as part of a long-term homeostatic mechanism, and not as an acute, mealrelated anorectic agent (the reasoning for this conclusion is given in an excellent and somewhat prophetic review by Weigle [10] ).
But the situation is clearly more complicated, because leptin also appears to accelerate the rate of metabolism and selectively to suppress the synthesis of fat [2] [3] [4] . Both actions can be inferred from studies with thefa/fa Zucker rat -homozygous for a mutant form of the fatty (fa) gene -which is thought to be the rat equivalent of the db/db mouse [11] and, as such, to lack the receptor for leptin. At only two days of age, the pre-obesefa/fa pups (identified retrospectively) showed clear signs of defective thermoregulation and increased adiposity. They also laid down excess fat when fed an identical diet as their lean littermates [12, 13] . Clearly, if their primary genetic defect is an inability to respond to leptin, this must manifest itself in a metabolic abnormality that promotes fat accretion and hypothermia, and which is independent of, and likely to precede, the associated hyperphagia.
What controls leptin? On teleological grounds, it is tempting to suggest that insulin plays an important role. This notion stems from the following considerations. If, in a broad sense, fat deposition is viewed as one of the major end points of insulin's anabolic actions, it would not be unreasonable to suppose that, upon reaching 'fullness', fat cells transmit a feedback signal to body centers controlling fat synthesis and caloric intake. The signal could be leptin, its site of action the hypothalamus (and/or elsewhere), and the result a suppression of insulin secretion and appetite through autonomic control relayed to the pancreatic cell and elements of the gastrointestinal tract. The following very recent observations would at least be consistent with such a viewpoint.
The first is that, with the exception of the ob/ob mouse, all forms of rodent obesity examined to date, both genetic and non-genetic, exhibit marked elevations in their plasma leptin levels [3, 14, 15] , and they are all hyperinsulinemic. Secondly, in most of these models, including the ob/ob mouse, the mRNA for leptin is overexpressed in fat tissue [3, [14] [15] [16] . Although exceptions have been noted [15] , these require confirmation; the issue of whether leptin expression varies in different fat depots also remains to be clarified. Thirdly, obesity in humans, which is also characterized by hyperinsulinemia, is accompanied by increased leptin mRNA levels and protein in fat depots and blood, respectively [15, 17, 18] . Fourthly, in both rodents and humans, leptin production appears to correlate positively with body fat mass, is suppressed during fasting and increases with refeeding [14, 15, [17] [18] [19] [20] ; insulin secretion has a similar profile. Importantly, the stimulatory effect of refeeding on leptin mRNA levels in rat adipose tissue was shown to be mediated by the attendant increase in circulating insulin concentrations and not. by the hyperglycemia [19] . Fifthly, leptin mRNA levels are down-regulated in rats treated with streptozotocin, an effect that is reversed by insulin treatment of the animals [20] . And lastly, during differentiation of murine preadipocytes into adipocytes, synthesis of leptin mRNA occurs concomitantly with the expression of other insulin-responsive genes [20] .
What seems to hold in all of the above situations is the close association between hyperleptinemia and hyperinsulinemia, raising the possibility that there exists a 1-cell-adipose tissue axis mediated by insulin and leptin, as depicted schematically in Figure 1 (whether the other 1-cell product, amylin, is involved remains to be seen). Should the scheme have validity, defects in any of its components could be predicted to lead to obesity. These would include failure to produce leptin (as in the ob/ob mouse), resistance to leptin action (as in the db/db mouse), or some other defect (for example, at the level of the CNS or the pancreatic cell) that causes oversecretion of insulin as an early event [9, 21, 22] . This last scenario, especially when coupled with hyperphagia, might be expected to promote overproduction of very low density lipoprotein (VLDL) triglyceride by the liver. With time, excessive delivery of VLDL to fat depots would result in increased adiposity and secondary hyperleptinemia, the latter attempting to act as a lipostatic device. As noted previously [22] , chronic exposure of muscle tissue to lipid substrates is a potentially important factor in the development of insulin resistance, a characteristic feature of all obesity/non-insulin-dependent diabetes syndromes.
The question where leptin fits in the etiology of human obesity, which almost certainly is polygenic in origin, is still a matter of speculation. Present indications are that mutations in the leptin gene are not commonplace in the human population [23] . Indeed, it is beginning to appear that the majority of overweight people, just like their rodent counterparts, overexpress a normal leptin moliecule in proportion to their fat mass [15, 17, 18] . It might be argued that such individuals are both insulin and leptin resistant. What impact this will have on the potential usefulness of recombinant leptin for the treatment of human obesity, should this be contemplated, will undoubtedly be a much debated issue in the near future.
